
Casa " Azioni " Azioni NASDAQ / Borsa valori NASDAQ " Buy Gilead Sciences Stocks
Are you looking to buy Gilead Sciences stocks? Chech our Reportlab with an in-depth review, check prices, statistics and see if buying this stock is interesting right now. This article will help you buy NASDAQ:GILD! and analyze the company to see if this stock might be an interesting option to invest in. We will enlighten you about Gilead Sciences stocks and how to buy and use them. Click on the button to start reading the review right now or scroll down for real time statistics about this company.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company’s products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; oNKo-innate Pty. Ltd.; Roche Holding AG; and Vir Biotechnology, Inc. The company has partnership with Arcus Biosciences, Inc. to co-develop and co-commercialize next-generation cancer immunotherapies. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California.
Volume medio
9.80 million shs
TAPPA DEL MERCATO
$85.24 billion
Borsa valori
NASDAQ
Compri queste azioni!
NOME
|
TICKER
|
INDUSTRIA
|
SETTORE
|
VOLUME
|
COMPRI ORA QUESTE AZIONI
|
---|---|---|---|---|---|
NASDAQ:GILD
|
Prodotti biologici, eccetto diagnostici
|
Medico
|
307,802 shs
|
Below is a quick guide on how to buy NASDAQ:GILD stocks safe, fast and around the world in less than five minutes.
Passo 1: Aprire un conto con eToro – eToro is the best broker to buy Gilead Sciences shares in the world as you won’t pay any commissions. To do this, visit the eToro website and open an account, it is 100% safe and they offer a huge amount of stocks.
Passo 2: caricare il suo ID - Come da regolamento KYC eToro le chiederà di caricare una copia del suo passaporto o della sua patente di guida.
Passo 3: Deposito di fondi - Depositi del denaro nel suo conto eToro appena creato. Può scegliere tra bonifico bancario, e-wallet o carta di debito/credito o Paypal.
Passo 4: Buy Gilead Sciences – Search for “”NASDAQ:GILD”” and click on the “”Trade”” button. Enter the total amount of your investment (minimum $50) and confirm the order by clicking the “”Open Trade”” button. And that’s it: you have just bought Gilead Sciences stocks with 0% commission!.
1 | ![]() | Deposito minimo $50 Promozione esclusiva | Il nostro punteggio 10 ★★★★★ | 0% commissione |
26 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Gilead Sciences in the last twelve months. There are currently 2 sell ratings, 12 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should “hold” Gilead Sciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GILD, but not buy additional shares or sell existing shares.
Wall Street analysts have given Gilead Sciences a “Hold” rating, but there may be better short-term opportunities in the market. Some of Reportlab’s past winning trading ideas have resulted in 5-15% weekly gains. Reportlab just released five new trading ideas, but Gilead Sciences wasn’t one of them. Reportlab thinks five stocks may be even better buys in the how to buy stocks guide.
1 | ![]() | Deposito minimo $50 Promozione esclusiva | Il nostro punteggio 10 ★★★★★ | 0% commissione |
2 | ![]() | Deposito minimo $50 Promozione esclusiva | Il nostro punteggio 10 ★★★★★ | 0% commissione |
3 | ![]() | Deposito minimo $50 Promozione esclusiva | Il nostro punteggio 10 ★★★★★ | 0% commissione |
It can be difficult to navigate through all the outdated and incorrect information related to purchasing NASDAQ:GILD stocks. We believe that stocks should be accessible for all, which is why we’ve created this handy guide on where to buy Gilead Sciences stocks with a step by step approach.
You’ll need to register with a broker, in these times you can’t go without once and it’s crucial to use a regulated broker that’s allowed to operate there, otherwise, you risk losing funds. eToro is one such broker, and one of the best brokers to buy Gilead Sciences stocks with 0% comission, to sign up just click on open account in the following table or compare other options.
Poiché eToro è una piattaforma regolamentata, dovrà completare il processo KYC, questa è una pratica standard e richiede solo un paio di minuti. Dovrà fornire un documento d'identità con foto (passaporto, patente) e una prova di indirizzo (bolletta, estratto conto bancario).
Una volta iscritto e verificato il suo conto, dovrà depositare dei fondi. eToro accetta carte di credito/debito, trasferimenti bancari e anche portafogli elettronici. Quindi qualunque sia la sua preferenza ci sarà qualcosa per lei.
Now that you’ve funded your eToro account, just type “NASDAQ:GILD stocks" nella barra di ricerca nella parte superiore dello schermo e prema "trade".
All that’s left is to buy some NASDAQ:GILD stock. Simply enter the amount you want to purchase and hit the “buy” button. The amount you bought will be automatically credited to your account where you can monitor its performance.
All in all, NASDAQ:GILD is an incredibly interesting company that has the potential to solve some major issues in the business space. After reading this guide you should know how to buy this investment using the best broker or platform. We recommend eToro to anyone looking for a regulated, easy-to-use, fully-featured broker to buy Gilead Sciences stocks. As with any broker or online platform, it’s crucial you set up 2FA when using their tools as it ensures your funds are completely safe.
Gilead Sciences is scheduled to release its next quarterly earnings announcement on Thursday, April 29th 2021.
View our earnings forecast for Gilead Sciences.
Gilead Sciences, Inc. (NASDAQ:GILD) announced its quarterly earnings results on Thursday, February, 4th. The biopharmaceutical company reported $2.19 EPS for the quarter, beating the Zacks’ consensus estimate of $2.15 by $0.04. Gilead Sciences had a net margin of 5.48% and a trailing twelve-month return on equity of 37.77%.
View Gilead Sciences’ earnings history.
Gilead Sciences’ stock was trading at $73.70 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GILD stock has decreased by 7.7% and is now trading at $68.06.
Gilead Sciences announced a quarterly dividend on Thursday, February 4th. Stockholders of record on Monday, March 15th will be paid a dividend of $0.71 per share on Tuesday, March 30th. This represents a $2.84 annualized dividend and a dividend yield of 4.17%. The ex-dividend date of this dividend is Friday, March 12th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.68.
View Gilead Sciences’ dividend history.
Launched in 2006, eToro is, in our opinion, without a doubt the best broker for buying NASDAQ:GILD stocks in the world. The onboarding process is simple, it’s designed to make sure even those new to the stock market are ready to start investing the shortest amount of time possible. As a regulated platform you gain several benefits, most importantly, you know they’re not going to run off with your hard-earned money./
Oltre 95% dei fondi dei clienti sono tenuti offline, in depositi freddi, il che è fondamentale per qualsiasi broker che gestisce i suoi beni. Indipendentemente da quanto sia sicura una piattaforma, raccomandiamo di usare 2FA per aggiungere un ulteriore livello di sicurezza al suo conto.
eToro offre agli utenti una serie di caratteristiche per iniziare ad investire il più rapidamente possibile. Hanno una caratteristica relativamente unica chiamata copy trading, che le permette di guadagnare un reddito passivo facendo da specchio a trader esperti, questo le permette di iniziare a guadagnare rapidamente e le dà una migliore comprensione delle strategie usate dai professionisti. Inoltre, eToro permette agli utenti di investire in portafogli gestiti, un portafoglio gestito è una varietà di asset simili raggruppati insieme, che le permette di diversificare il suo conto, riducendo qualsiasi rischio potenziale. Per chi ha esperienza di trading precedente, può investire in mercati al di fuori delle azioni, dato che eToro permette agli utenti di commerciare ETF, materie prime, cripto e indici. Se già investe al di fuori dello spazio del mercato azionario questo può essere molto utile, perché le permette di gestire tutti i suoi investimenti in un solo posto.
Gilead Sciences pays an annual dividend of $2.72 per share and currently has a dividend yield of 3.97%. GILD has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio of Gilead Sciences is 44.30%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Gilead Sciences will have a dividend payout ratio of 38.80% next year. This indicates that Gilead Sciences will be able to sustain or increase its dividend.
View Gilead Sciences’ dividend history.
Gilead Sciences updated its FY21 earnings guidance on Thursday, February, 4th. The company provided earnings per share (EPS) guidance of $6.75-7.45 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.90. The company issued revenue guidance of $23.70-25.10 billion, compared to the consensus revenue estimate of $24.49 billion.
I CFD sono strumenti complessi e comportano un alto rischio di perdere denaro rapidamente a causa della leva. Il 68% dei conti degli investitori al dettaglio perdono denaro quando scambiano CFD con questo fornitore. Deve considerare se capisce come funzionano i CFD e se può permettersi di correre l'alto rischio di perdere i suoi soldi.
26 brokers have issued twelve-month price targets for Gilead Sciences’ shares. Their forecasts range from $61.00 to $625.00. On average, they expect Gilead Sciences’ stock price to reach $96.07 in the next year. This suggests a possible upside of 41.2% from the stock’s current price.
View analysts’ price targets for Gilead Sciences or view top-rated stocks among Wall Street analysts.
Gilead Sciences saw a drop in short interest in the month of December. As of December 31st, there was short interest totaling 17,670,000 shares, a drop of 14.8% from the December 15th total of 20,730,000 shares. Based on an average daily trading volume, of 9,390,000 shares, the days-to-cover ratio is currently 1.9 days. Approximately 1.4% of the company’s stock are short sold.
View Gilead Sciences’ Short Interest.
Gilead Sciences’ management team includes the following people:
Mr. Daniel P. O’Day, Chairman & CEO (Age 57, Pay $10.86M)
Mr. Andrew D. Dickinson, Exec. VP & CFO (Age 51, Pay $6.91M)
Mr. Brett A. Pletcher, Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. (Age 53, Pay $2.14M)
Ms. Johanna Mercier, Chief Commercial Officer (Age 51, Pay $2.55M)
Dr. Merdad V. Parsey M.D., Ph.D., Chief Medical Officer (Age 58, Pay $1.12M)
Ms. Diane E. Wilfong, Sr. VP, Corp. Controller & Chief Accounting Officer (Age 59)
Ms. Jyoti K. Mehra, Exec. VP of HR
Dr. William A. Lee, Exec. VP of Research (Age 66)
Dr. Taiyin Yang, Exec. VP of Pharmaceutical Devel. & Manufacturing (Age 67)
Dr. Diana Brainard M.D., Sr. VP of HIV & Emerging Viral Infections (Age 50)
107 employees have rated Gilead Sciences CEO Daniel O’Day on Glassdoor.com. Daniel O’Day has an approval rating of 92% among Gilead Sciences’ employees. This puts Daniel O’Day in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
1 | ![]() | Deposito minimo $50 Promozione esclusiva | Il nostro punteggio 10 ★★★★★ | 0% commissione |
Some companies that are related to Gilead Sciences include Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seagen (SGEN), Alexion Pharmaceuticals (ALXN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), Novavax (NVAX), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and United Therapeutics (UTHR).
View all of GILD’s competitors.
Based on aggregate information from Reportlab watchlists, some companies that other Gilead Sciences investors own include NVIDIA (NVDA), The Walt Disney (DIS), Micron Technology (MU), Intel (INTC), Alibaba Group (BABA), Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), Netflix (NFLX) and Johnson & Johnson (JNJ).
Gilead Sciences trades on the NASDAQ under the ticker symbol “GILD.”
Gilead Sciences’ stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (8.87%), California Public Employees Retirement System (0.81%), Swiss National Bank (0.50%), Sumitomo Mitsui Trust Holdings Inc. (0.40%), First Trust Advisors LP (0.18%) and Candriam Luxembourg S.C.A. (0.18%). Company insiders that own Gilead Sciences stock include Brett A Pletcher, Diane E Wilfong, Gayle E Wilson, Javier Rodriguez, John Francis Cogan, Merdad Parsey, Olsen Per Wold and Richard James Whitley.
View institutional ownership trends for Gilead Sciences.
GILD stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., First Trust Advisors LP, PGGM Investments, Sumitomo Mitsui Trust Holdings Inc., NN Investment Partners Holdings N.V., California Public Employees Retirement System, DNB Asset Management AS, and Bartlett & Co. LLC. Company insiders that have sold Gilead Sciences company stock in the last year include Brett A Pletcher, Diane E Wilfong, Gayle E Wilson, Javier Rodriguez, John Francis Cogan, and Merdad Parsey.
View insider buying and selling activity for Gilead Sciences or view top insider-selling stocks.
GILD stock was purchased by a variety of institutional investors in the last quarter, including KAMES CAPITAL plc, Assenagon Asset Management S.A., State of Michigan Retirement System, Candriam Luxembourg S.C.A., McCarthy Asset Management Inc., Victory Capital Management Inc., Private Management Group Inc., and Sprucegrove Investment Management Ltd..
View insider buying and selling activity for Gilead Sciences or or view top insider-buying stocks.
A Reportlab.org vogliamo assicurarci che lei abbia tutte le informazioni più rilevanti su acquisto di azioni. Le portiamo le migliori guide sul mercato azionario con recensioni personali, informazioni di base, recensioni di piattaforme, how to's e altro. Vuole ottenere altre informazioni? Allora dia un'occhiata al Azioni OTC, Azioni del NASDAQ, Azioni del NYSE, Azioni LON, Scorte FRA, Azioni ETR, Scorte dell'EPA, Azioni del TSX o Azioni Amex. Cercando informazioni più dettagliate come 5g stock, azioni biotecnologiche, azioni d'oro e altre informazioni dal nostro reportlab.
How can you buy Gilead Sciences stock on the internet?
You can easily buy Gilead Sciences stocks with one of the well known regulated brokers on the internet. You can open an account within 5 minutes, make deposits with countless payment providers and trade with professional tools on their platform. At the moment, our visitors rate eToro as the most popular choice.
Un'altra opzione è usare un broker regolamentato come Mercati IC o Brokers interattivi. You can an account with these brokers and start buying or trading NASDAQ:GILD stocks in a safe and complete environment to trade in.
Where to buy Gilead Sciences stock?
You will first want to find a licensed broker that supports NASDAQ:GILD stock. One of our favourite brokers, eToro for example, allows you to make investments into this asset from just $25 and only charges you the spread. Another option is using a regulated broker like DEGIRO or Interactive Brokers. You can open an account with these brokers and start buying or trading NASDAQ:GILD stocks in a safe and complete environment.
Is NASDAQ:GILD stock a good investment?
As with any other asset, there is an element of risk associated with buying NASDAQ:GILD stocks. Therefore, you will want to study the market and make a decision based on your financial standing and the risk you are willing to take.
Is Gilead Sciences stock safe to invest in?
All stocks are volatile, or affected by market circumstances. The case with NASDAQ:GILD is no different, with its price fluctuating dramatically within short periods. As such, if the market goes against you, then you will end up facing a loss. We advice you to do research first before investing in Gilead Sciences stock.
How do you trade Gilead Sciences stocks?
You can trade stocks by first opening an account with a regulated platform and making a deposit in US dollars, EUROs or other currency. Next, search for Gilead Sciences stock and choose from a buy or sell order – depending on whether you think the stock asset will rise or fall in value. If you speculated on NASDAQ:GILD stocks correctly, you will have made a profit. The size of your trading profit will ultimately be determined by your stake and at what percentage your position grew.
How to sell Gilead Sciences stock?
To sell your NASDAQ:GILD stocks investment, you can sign in to your broker account and cash out directly from within your portfolio. If you have stored the stocks elsewhere, you will first have to transfer them to a third-party provider or broker to cash out.
What is the best Gilead Sciences stock trading platform?
eToro, is a top-rated platform for beginners, albeit, it charges significantly lower fees. For example, there are no fees to deposit with a debit/credit card and you only need to cover the spread when trading NASDAQ:GILD stock.
Stephen conosce molto bene i prodotti finanziari e in particolare ha una grande passione per i mercati azionari e i suoi partecipanti. Speriamo che le informazioni fornite le siano utili. C'è qualcosa di poco chiaro? Lasci le sue domande o commenti in fondo alla pagina.
![]() | Il nostro punteggio ★★★★★ | |
![]() | Il nostro punteggio ★★★★★ | |
![]() | Il nostro punteggio ★★★★★ |
Notiziario
![]() |
Il nostro punteggio |
0% commissione |
Dati in tempo reale su azioni e criptovalute
Notifiche, Consigli e Notizie
Le migliori guide su azioni e criptovalute
Recensioni su broker e scambi online
Reportlab Finanza è un sito web puramente informativo e non implica in nessun caso consigli di investimento. Tutti gli investimenti comportano rischi e lei può perdere tutti i suoi investimenti. Non investa denaro che non può permettersi di perdere.
Reportlab Finanza
38 Holburn Lane
Heckfield Green
IP21 0UB
Regno Unito
Copyright © 2022 Reportlab.Finance | Tutti i diritti riservati.